Nanexa AB (NANEXA) - Total Liabilities

Latest as of March 2026: Skr39.57 Million SEK ≈ $4.26 Million USD

Based on the latest financial reports, Nanexa AB (NANEXA) has total liabilities worth Skr39.57 Million SEK (≈ $4.26 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Nanexa AB equity growth rate to track the company's year-over-year net asset growth rate.

Nanexa AB - Total Liabilities Trend (2014–2025)

This chart illustrates how Nanexa AB's total liabilities have evolved over time, based on quarterly financial data. See Nanexa AB (NANEXA) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Nanexa AB Competitors by Total Liabilities

The table below lists competitors of Nanexa AB ranked by their total liabilities.

Company	Country	Total Liabilities
Coloray International Investment Co. Ltd KQ:900310	Korea	₩40.22 Billion
Geodrill Limited TO:GEO	Canada	CA$59.08 Million
OSE Pharma SA PA:OSE	France	€53.58 Million
Alcadon Group AB ST:ALCA	Sweden	Skr737.80 Million
HyVision System. Inc KQ:126700	Korea	₩50.51 Billion
Daehan Synthet KO:003830	Korea	₩127.57 Billion
Hektar Real Estate Investment Trust KLSE:5121	Malaysia	RM707.97 Million
Artiva Biotherapeutics, Inc. Common Stock NASDAQ:ARTV	USA	$19.64 Million

Liability Composition Analysis (2014–2025)

This chart breaks down Nanexa AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NANEXA stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.06	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.31	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.24	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Nanexa AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Nanexa AB (2014–2025)

The table below shows the annual total liabilities of Nanexa AB from 2014 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr36.61 Million ≈ $3.94 Million	+75.21%
2024-12-31	Skr20.90 Million ≈ $2.25 Million	-42.64%
2023-12-31	Skr36.43 Million ≈ $3.92 Million	-40.38%
2022-12-31	Skr61.10 Million ≈ $6.58 Million	+345.88%
2021-12-31	Skr13.70 Million ≈ $1.47 Million	+32.52%
2020-12-31	Skr10.34 Million ≈ $1.11 Million	-2.08%
2019-12-31	Skr10.56 Million ≈ $1.14 Million	-9.05%
2018-12-31	Skr11.61 Million ≈ $1.25 Million	+103.42%
2017-12-31	Skr5.71 Million ≈ $614.26K	+57.47%
2016-12-31	Skr3.62 Million ≈ $390.09K	+109.73%
2015-12-31	Skr1.73 Million ≈ $185.99K	+54.67%
2014-12-31	Skr1.12 Million ≈ $120.25K	--

About Nanexa AB

ST:NANEXA Sweden Drug Manufacturers - Specialty & Generic

Market Cap

$82.83 Million

Skr769.64 Million SEK

Market Cap Rank

#19821 Global

#351 in Sweden

Share Price

Skr4.17

Change (1 day)

-2.80%

52-Week Range

Skr1.61 - Skr4.92

All Time High

Skr15.20